| EQ-5D Utility Value | EQ-VAS Score | NEI-VFQ-25 Composite Score | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Coef. | p-value | 95% CIs | Coef. | p-value | 95% CIs | Coef. | p-value | 95% CIs | ||
Area | Rural | 0.085 | 0.005 | (0.026, 0.145) | -0.624 | 0.678 | (-2.317, 3.564) | -1.171 | 0.564 | (-5.143, 2.802) |
Gender | Female | 0.094 | 0.039 | (0.005, 0.183) | 3.010 | 0.180 | (-1.391, 7.412) | 4.630 | 0.127 | (-1.315, 10.576) |
Employment status | Employed | 0.134 | 0.002 | (0.050, 0.219) | 3.404 | 0.111 | (-0.777, 7.586) | 3.678 | 0.202 | (-1.970, 9.326) |
Duration of Diabetes | 11–15 years | 0.033 | 0.393 | (-0.043, 0.110) | 1.087 | 0.558 | (-2.556, 4.73) | 4.717 | 0.070 | (-0.382, 9.816) |
> 15 years | -0.013 | 0.685 | (-0.078, 0.052) | -4.209 | 0.010 | (-7.411, -1.006) | -0.337 | 0.879 | (-4.663, 3.989) | |
Stage of DR | NPDR | 0.080 | 0.111 | (-0.018, 0.178) | 3.291 | 0.183 | (-1.555, 8.137) | -0.374 | 0.911 | (-6.919, 6.172) |
PDR | 0.070 | 0.027 | (0.008, 0.132) | 1.018 | 0.514 | (-2.037, 4.073) | 3.001 | 0.154 | (-1.126, 7.128) | |
NPDR + ME | 0.061 | 0.234 | (-0.040, 0.162) | 1.098 | 0.665 | (-3.874, 6.070) | -1.490 | 0.664 | (-8.206, 5.226) | |
Visual acuity better eye | Mild | -0.011 | 0.795 | (-0.094, 0.072) | -2.686 | 0.197 | (-6.762, 1.390) | -2.640 | 0.347 | (-8.146, 2.866) |
Moderate | -0.175 | 0.000 | (-0.251, -0.099) | -12.472 | 0.000 | (-16.222, -8.723) | -29.765 | 0.000 | (-34.830, -24,701) | |
Severe | -0.469 | 0.000 | (-0.566, -0.373) | -25.196 | 0.000 | (-29.967, -20.425) | -60.031 | 0.000 | (-66.475, -53.587) | |
Blind | -0.637 | 0.000 | (-0.727, -0.547) | -34.949 | 0.000 | (-39.370, -30.527) | -71.688 | 0.000 | (-77.660, -65.716) | |
Co-morbidities | No | -0.140 | 0.001 | (-0.222, -0.058) | -2.407 | 0.243 | (-6.450, 1.637) | -4.700 | 0.092 | (-10.162, 0.762) |
Constant | 0.706 | 0.000 | (0.497, 0.916) | 72.006 | 0.000 | (61.687, 82.326) | 86.310 | 0.000 | (79.085, 93.535) | |
R square | 0.563 | 0.568 | 0.774 | |||||||
Adjusted R square | 0.522 | 0.548 | 0.757 |